tralokinumab is an approved drug (EMA & FDA (2021))
Compound class:
Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
References |
1. Adams B.
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease. Accessed on 09/02/2018. Modified on 09/02/2018. fiercebiotech.com, https://www.fiercebiotech.com/biotech/sanofi-ditches-il4-il13-antibody-drug-lung-scarring-disease |
2. Thom G, Minter R. (2012)
Optimization of CAT-354, a therapeutic antibody directed against interleukin-13, using ribosome display. Methods Mol Biol, 805: 393-401. [PMID:22094818] |
3. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. (1998)
Interleukin-13: central mediator of allergic asthma. Science, 282 (5397): 2258-61. [PMID:9856949] |
4. Wynn TA. (2003)
IL-13 effector functions. Annu Rev Immunol, 21: 425-56. [PMID:12615888] |